HOME >> MEDICINE >> NEWS
Heart failure medication does not improve survival, compared to more widely used medication

The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.

Acute decompensated heart failure (ADHF; severe heart failure characterized by inability of the heart to maintain adequate blood circulation) remains a common cause of hospitalization worldwide, but appropriate treatment is not always clear. Dobutamine improves symptoms but has been associated with an increased risk of death and other cardiovascular events, according to background information in the article. In a previous study, secondary analyses indicated that the drug levosimendan was associated with lower risk of death compared to dobutamine.

Alexandre Mebazaa, M.D., Ph.D., of the Universit Paris Diderot and Hospital Lariboisire AP-HP, Paris, and colleagues with the SURVIVE trial (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) conducted a study in which the primary purpose of the trial was to assess long-term survival outcomes for 1,327 ADHF patients who received levosimendan or dobutamine. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Patients received either intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663).

The researchers found that during the 180 days after drug infusion, there were 173 deaths (26 percent) in the levosimendan group and 185 deaths in the dobutamine group (28 percent). There were no statistical differences between treatment groups for most secondary end points (all-cause death at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea (difficulty breathing) at 24 hours, and cardiovascular death at 180 days). Compared with dobutamine-treated patients, levosimendan-treated patients were less likely to expe
'"/>

Contact: Katherine Morales
214-648-3404
JAMA and Archives Journals
1-May-2007


Page: 1 2

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. Heart-failure patients benefit from pharmacist care
3. Study offers clues to Broken Heart Syndrome
4. Heart Failure 2007
5. UCLA neurologist honored with American Heart Associations Stroke Council Award
6. Heart failure: Mayo Clinic reveals abnormality in filling of the heart is frequent culprit
7. Heart catheters do not benefit patients
8. Heart Rhythm Society publishes final recommendations for heart patients
9. Heartburn drug may help to slow progression of chronic heart failure
10. Heart failure drugs may be beneficial for patients with hardening of the arteries
11. University of Kentucky Gill Heart researchers study abdominal aortic aneurysms

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... has announced the Best Memory Care Facilities in Louisville, KY. The guide identifies ... amenities. , According to the Alzheimer’s Association , 5.6 million people ...
(Date:9/1/2020)... ... , ... KitoTech Medical, a Seattle-based medical device company, announced ... used to accelerate the commercialization of its microMend® family of wound closure products. ... expand its customer base of healthcare systems as well as independent hospitals and ...
(Date:8/31/2020)... ... 2020 , ... Cardiothoracic surgeons at Allegheny General Hospital (AGH), ... University (CMU) to develop a new heart monitoring device designed to serve as ... The AGH/CMU team was recently awarded a “Trailblazer” grant from the National Institutes ...
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break up your ... Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign in the United ... STEPtember meets everyone wherever they are at this moment — encouraging people to move ...
(Date:8/31/2020)... ... ... and topsy-turvy economic outlook continues to put financial strain on many of us, so it ... from our monthly expenses and put more into savings, if possible. , “That’s a great ... safety net in place in case something were to happen to you,” says Lee Duncan, ...
Breaking Medicine News(10 mins):
(Date:9/2/2020)... ... September 02, 2020 , ... ... Penetration Technology, LLC, (APT) a Texas- and Indiana-based company ( http://www.aptt3x.com ) ... Counter (OTC) products, was today provided results of an independent laboratory evaluation ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... and Director of Cosmetics and Laser Surgery at the University of Rochester Medical ... Surgery fellowship at SkinCare Physicians in Boston, with clinical faculty from the Harvard ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are ... (CDC), About 3% of breast cancers (about 7,500 women per year) and 10% of ... and BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic Testing ...
Breaking Medicine Technology:
Cached News: